Stock & Company Details
Artelo Biosciences Inc $ARTL
Price:
46,691,331
3.5M
$3.9M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
0.00
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Retail Trade
ARTL technical indicators
Latest Artelo Biosciences Inc (ARTL) technical indicators as of 2026-07-01: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
29.70 2.0%
MACD:
-0.26 4.0%
SMA 50:
$2.01 3.3%
SMA 200:
$2.87 0.7%
EMA 20:
$1.32 1.7%
Bollinger Bands:
1.47 / 1.05
Stochastic:
22.55 24.2%
ADX 14:
20.28 5.0%
ATR 14:
0.16 2.8%
CCI 20:
-136.62 1.1%
OBV:
185.80M 0.4%
ROC 12:
-19.12% 26.2%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.
Finance Bot
Ask your questions
Start by typing a question below.
